| answer text |
<p>The Department has no plans to carry out an impact assessment on the 2023 payment
percentage. The Department’s standard practice is to set the payment percentage based
on measured sales. The payment percentage projected for 2023 is in line with Department
projections shared with industry when the Voluntary Scheme for Branded Medicines Pricing
and Access (VPAS) was agreed.</p><p>We have seen no evidence that increased VPAS payments
have or will impact on the supply of medicines to the National Health Service. Where
payment rates may put pressure on the profitability of individual products, there
are provisions in the scheme for companies to apply for a price increase.</p>
|
 |
